Zelboraf, skin cancer medicine, has gotten approval from European Drug Regulators

Zelboraf
Zelboraf tablets

Roche has announced, on Monday, that the European Drug Regulators have approved the company’s new skin cancer medicine, i.e. Zelboraf (vemurafenib), for treating the fatal skin cancer; BRAF V600 mutation-positive unresectable or metastatic melanoma.

Melanoma is usually curable in early stages but it becomes most aggressive and deadliest form of cancer, when it spreads to other parts of the body. Only one in four patients with metastatic melanoma are expected to live for one year after diagnosis otherwise patients with metastatic melanoma have an average half life in months. Mutations of BRAF protein occurs in almost 50% of all melanomas and 8% of solid cancer tumors.

Zelboraf can be used as a monotherapy for the treatment of adult patients, whose late stage skin cancer have spread to other parts of the body and become inoperable. It can be given as a twice daily pill.

“Today’s approval is important news for people with BRAF mutation-positive metastatic melanoma as Zelboraf significantly improves patient survival and exemplifies the benefits that Roche’s personalized approach to medicine can provide for patients, physicians and society,” said Hal Barron, M.D., Chief Medical Officer and Head, Global Product Development.

Roche has developed medicines along with diagnostic tests, so that patients and doctors can check whether the patient will be benefitted from the medicine or not.

Further Reading:

Roche

saypeople

SayPeople.com gives you the news and information about Science, Research, Technology, Business and Islam.